Clinical Trial: Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

U.S., Aug. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07749716) titled 'Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata' on Aug. 03.

Brief Summary: This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical study designed to evaluate the efficacy and safety of VC005 tablets in subjects with severe alopecia areata (AA).

Study Start Date: Aug. 15

Study Type: INTERVENTIONAL

Condition: Alopecia Areata

Intervention: DRUG: Drug: VC005 tablets

VC005 repeat administration for 24 weeks

DRUG: VC005 tablets

VC005 repeat administration for 24 weeks

DRUG: VC005 placebo tablets

VC005 placebo repeat administration for 24 weeks

Recruitment Sta...